ETANA AND THE FACULTY OF MILITARY PHARMACY OF UNHAN ESTABLISH STRATEGIC PARTNERSHIP

Jakarta, June 12, 2025 – Etana Biotechnologies Indonesia (Etana) has officially entered into a partnership with the Faculty of Military Pharmacy of University of Defense (Unhan) to strengthen collaboration in education, research, and community service. The memorandum of understanding was signed by Etana President Director, Nathan Tirtana, and Dean of the Faculty of Military Pharmacy of Unhan, Prof. Dr. apt. Yahdiana Harahap, M.S., at Etana’s office in Jakarta on Thursday (June 12).

This collaboration marks a key milestone in a long-term partnership that aims to make a tangible impact on the development of Indonesia’s healthcare sector and serves as part of Etana’s meaningful contribution to realizing the vision of Indonesia Emas 2045.

“Through this partnership, we aim to support educational development actively, particularly through innovative research in pharmacy and biotechnology, as well as community service, which are fundamental pillars for developing excellent human resources,” said Nathan.

Nathan further emphasized that collaboration with academic institutions like Unhan is a strategic step to strengthen the nation’s capacity to address future health challenges and to build a resilient and sustainable national healthcare system.

“We believe that synergy between the industry and academic institutions will reinforce national health resilience and accelerate the independence of Indonesia’s pharmaceutical and vaccine industries,” Nathan explained.

Through this partnership, Etana reaffirms its commitment as a company that is focused on product development and actively contributes to building a sustainable healthcare ecosystem in Indonesia.

About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.